CMS Releases CY 2027 Medicare Advantage and Part D Proposed Rule

Medicare policy rarely arrives with fireworks, confetti, and a brass band. It usually shows up wearing a gray suit, carrying a binder, and politely asking everyone to please review page 417. But the CY 2027 Medicare Advantage and Part D proposed rule is one of those policy releases that matters far beyond Washington. It touches how seniors compare plans, how insurers get paid, how pharmacies and plans handle drug costs, and what happens when a doctor suddenly leaves a Medicare Advantage network.

In plain English, CMS is trying to do several things at once: make Medicare Advantage easier for beneficiaries to navigate, update the Star Ratings system, lock in major Part D redesign changes tied to the Inflation Reduction Act, and collect feedback on bigger questions about risk adjustment, competition, and care for dually eligible beneficiaries. That is a lot for one rule, but Medicare Advantage is no small side project anymore. More than half of eligible Medicare beneficiaries are now enrolled in Medicare Advantage plans, which means policy changes here can ripple across the entire health care market.

This article breaks down what the proposed rule says, why it matters, and what it could mean for beneficiaries, plans, providers, and anyone who has ever stared at a Medicare booklet and thought, “Surely there must be an easier way.”

Why the CY 2027 proposed rule matters now

CMS released the proposed rule at a moment when Medicare Advantage enrollment is huge, competition is intense, and scrutiny is rising. In 2025, 54% of eligible Medicare beneficiaries were enrolled in Medicare Advantage, and special needs plans continued growing fast. At the same time, policy analysts and MedPAC have kept pressing questions about payment accuracy, coding intensity, transparency, and whether the current quality system actually helps consumers pick better plans.

That backdrop helps explain the tone of the CY 2027 proposal. CMS is not merely tweaking a few technical lines. It is signaling a broader effort to refocus the program on outcomes, patient experience, and cleaner administration, while also asking for public input on the next chapter of Medicare Advantage policy.

Put differently, this is not just a housekeeping memo with a fancy title. It is a rule that asks: What should Medicare Advantage reward? What should Part D look like after the IRA redesign? And how do you protect beneficiaries without drowning plans, providers, and regulators in paperwork thick enough to stop a door?

What CMS is proposing in the CY 2027 rule

1. A major rethink of Medicare Advantage and Part D Star Ratings

One of the biggest headlines in the proposed rule is CMS’s plan to change how Star Ratings work. These ratings are important because they help beneficiaries compare plans and also influence bonus payments and rebate dollars. In other words, stars are not decorative. In Medicare Advantage, stars can affect real money and real benefits.

CMS proposed two major moves. First, the agency said it would not implement the Excellent Health Outcomes for All reward for the 2027 Star Ratings. That reward, previously called the Health Equity Index reward, was designed to recognize high performance for enrollees with certain social risk factors. Instead, CMS proposed continuing the historical reward factor that emphasizes consistently strong performance across all quality measures.

Second, CMS proposed to streamline the measure set by removing 12 measures tied largely to administrative processes and areas where plan performance had become so similar that beneficiaries could not meaningfully tell one plan from another. At the same time, CMS proposed adding a Part C Depression Screening and Follow-Up measure, a change that points toward more attention on behavioral health and clinically meaningful outcomes.

That shift is important for SEO audiences searching terms like CMS Star Ratings changes 2027 or Medicare Advantage quality measures. The policy message is clear: CMS wants the ratings system to focus less on procedural box-checking and more on patient-centered care. Plans, meanwhile, hear a different but equally clear message: if your internal strategy is built around gaming minor operational metrics, the game board may be changing.

2. Easier plan changes when providers leave a network

Anyone who has ever chosen a health plan partly because it includes a trusted physician knows that provider networks are not some tiny footnote. They are the plot. Under the proposal, CMS would make it easier for Medicare Advantage enrollees to switch plans when a provider leaves the plan network.

Today, the existing special enrollment period has been tied to whether CMS determines that the network change is “significant.” The proposed rule would remove that limitation. If one or more providers leave the network, affected enrollees could have a clearer path to changing coverage.

This may sound technical, but the real-world effect could be pretty personal. Imagine a beneficiary in ongoing cancer treatment, dialysis, or behavioral health care who suddenly learns a key provider is out of network. The current system can feel rigid. CMS is proposing a more practical approach that better reflects how disruptive provider terminations can be in real life.

The agency also proposed codifying its long-standing policy that certain special enrollment periods require prior CMS approval. That move is about transparency and guardrails: stakeholders would better understand how these enrollment options are created and changed.

3. Codifying the Inflation Reduction Act’s Part D redesign

The Medicare Part D proposed rule section is a big deal because it would formally write major IRA-related changes into regulation for 2027 and beyond. CMS had temporary authority through 2026 to implement these changes using program instructions. That temporary phase was always going to end. Now the agency is moving from “temporary operating manual” mode to “let’s put this into the rulebook” mode.

Among the biggest proposed codifications are the elimination of the coverage gap phase, a lower annual out-of-pocket threshold, no cost sharing in the catastrophic phase, and continued implementation of the Manufacturer Discount Program, which replaced the old Coverage Gap Discount Program. CMS also proposed technical updates involving True Out-of-Pocket costs, specialty-tier rules, reinsurance methodology, and the Selected Drug Subsidy.

For beneficiaries, the practical story is easier to understand than the regulatory wording. The modernized Part D benefit is meant to make prescription drug spending more predictable and more manageable. For plans and pharmacy stakeholders, however, the details matter a lot because they affect bid strategy, liability distribution, reporting, and compliance operations.

So yes, on one side this is a consumer affordability story. On the other side, it is an actuarial chess match played with spreadsheets, deadlines, and a suspicious amount of caffeine.

4. Requests for information that hint at bigger future reforms

Sometimes the most interesting part of a proposed rule is not the text that changes immediately. It is the text that asks, “What should we do next?” CMS included several broad requests for information, and they are worth watching.

The first RFI focuses on risk adjustment, competition, and quality bonus payments. CMS flagged concerns that the current system may disadvantage smaller or newer plans and may also encourage coding practices that do not necessarily reflect better care. The agency asked about alternative data sources, ways to reduce gaming, and even how artificial intelligence or machine learning might someday support future risk-adjustment methods.

The second RFI looks at special needs plans, especially the growth of chronic condition special needs plans and how dually eligible beneficiaries are being served. This matters because enrollment in SNPs has been rising fast, and policymakers increasingly care about whether vulnerable beneficiaries are receiving truly integrated Medicare-Medicaid care rather than fragmented versions of it.

The third RFI focuses on well-being and nutrition. That may sound softer than payment policy, but it is actually pretty revealing. CMS is asking whether future Medicare Advantage policy should do more to encourage nutrition support, emotional well-being, social connection, and preventive care. In other words, the agency is peeking beyond traditional medical utilization and asking how plans can support healthier lives, not just cleaner claims files.

5. Clarifying rules for cannabis-related supplemental benefits

Another notable provision would refine the rules on cannabis-related products under Special Supplemental Benefits for the Chronically Ill. CMS proposed clarifying that cannabis products that are illegal under applicable state or federal law, including the Federal Food, Drug, and Cosmetic Act, are not allowable SSBCI benefits.

This is less of a culture-war headline than a compliance clarification. The agency is trying to make the regulatory language more precise so plans know what is allowed, what is not, and where legal boundaries still apply. In a benefit environment where innovation sometimes moves faster than federal guidance, precision matters.

6. Reducing administrative burden

CMS also framed parts of the proposed rule as an effort to reduce regulatory burden. That includes reconsidering reporting and oversight requirements that may be duplicative, outdated, or not especially helpful for beneficiaries. This theme appears alongside the Star Ratings changes, data questions, and operational updates.

For health plans, that is welcome news on paper. For beneficiaries, the key question is whether less paperwork will actually lead to better service, or whether it simply gives organizations a slightly larger filing cabinet for the paperwork that remains. The success of the proposal will depend on whether simplification removes waste without weakening accountability.

What this proposed rule means for key stakeholders

For beneficiaries

The biggest beneficiary-facing changes are easier to grasp than most federal rulemaking. If the proposal becomes policy, seniors could see a ratings system that is more focused on meaningful performance, more predictable Part D drug coverage, and a better path to switching plans when provider networks change. That could make plan shopping less confusing and midyear disruptions less painful.

For health plans

Plans may need to rethink quality strategy, clinical outreach, compliance workflows, and long-range product design. The Star Ratings proposal especially matters because ratings are tied to rebate percentages that can help fund extra benefits, reduced premiums, and lower cost sharing. A quality system that rewards different things can ultimately reshape how plans allocate resources.

For providers and health systems

Providers should pay attention to the enrollment provisions and the future direction of risk adjustment. Network stability, data reporting, and plan-provider relationships remain central to Medicare Advantage operations. Hospitals and physician groups also have a stake in how CMS thinks about quality, coding, and the release of risk-adjustment-related data.

For policy watchers

This rule also matters as a signal. CMS is showing interest in payment accuracy, data transparency, behavioral health, integrated care for vulnerable populations, and more practical consumer protections. Even where the proposal does not finalize a sweeping reform today, it points to where tomorrow’s debate is heading.

Experience on the ground: what this rule feels like in real life

Rules are written in regulatory prose, but they land in actual kitchens, clinics, pharmacies, and call centers. So let’s talk about experience.

Picture a Medicare Advantage member named Linda. She chose her plan because it covered her cardiologist, her neighborhood hospital, and the prescription drugs she takes every month. Then halfway through the year, she gets a letter saying one of her key providers is leaving the network. For beneficiaries like Linda, the CY 2027 proposed rule matters because it acknowledges a simple truth: when a provider leaves, this is not a paperwork issue. It is a stress issue. It is a trust issue. It is an “I finally understood my coverage and now everything moved again” issue.

Now picture a quality director at a health plan. For years, the team has tracked Star Ratings with the intensity of air traffic controllers. Dashboards, committee meetings, measure owners, intervention lists, reminders, audits, reheated coffee at 7:10 p.m. If CMS removes a dozen administrative measures and adds more focus on clinical outcomes and depression follow-up, that leader’s job changes overnight. Some old performance routines become less valuable. New clinical coordination efforts suddenly matter more. That can be exciting, but it can also feel like changing the tires while the car is still on the highway.

Then there is the pharmacist or Part D operations manager dealing with redesign changes. Beneficiaries mostly experience the drug benefit through one question: “What will I pay?” But behind that question sits a maze of TrOOP calculations, manufacturer discounts, subsidy reconciliation, reinsurance rules, and claims systems that all have to line up correctly. When CMS codifies IRA-driven Part D redesign policies, it creates more permanence. That is good for stability, but it also means organizations must translate policy into training, software, member communications, and customer service scripts that make sense to real people at real counters.

And finally, think about brokers, advocates, caregivers, and adult children helping a parent choose coverage. They do not read proposed rules for fun. They read them because every change in enrollment rights, plan comparisons, provider access, or drug affordability can affect a household’s budget and peace of mind. Their lived experience of Medicare is not theoretical. It is a phone call after a denial. It is a search for an in-network specialist. It is comparing plans at the kitchen table with too many tabs open and not enough certainty.

That is why this proposed rule matters. It is about more than technical policy. It is about whether Medicare Advantage and Part D feel more understandable, more stable, and more fair to the people who rely on them. If CMS gets the balance right, beneficiaries may not notice the rule itself. They will simply notice fewer surprises. In health policy, that is often the best compliment possible.

Final takeaway

The CMS CY 2027 Medicare Advantage and Part D proposed rule is a meaningful policy package with both immediate and long-range implications. In the short term, it would update Star Ratings, ease plan changes when provider networks shift, and codify major Part D redesign policies already reshaping prescription drug coverage. In the longer term, it opens the door to bigger debates about risk adjustment, data use, quality incentives, nutrition, and how Medicare Advantage should evolve as enrollment keeps growing.

For beneficiaries, the best parts of the proposal are the ones that make the system more usable. For plans, the message is that performance, compliance, and benefit design are entering another adaptation cycle. For the broader market, the rule confirms that Medicare Advantage remains one of the most important policy battlegrounds in U.S. health care.

In other words, this is one of those Medicare rules that may look technical from 30,000 feet but feels very personal on the ground. And whenever a federal rule can affect your doctor, your drugs, your costs, and your choices, it is worth reading the fine print, even if the fine print occasionally tries to fight back.